Skip to Content

Amaryl FDA Alerts

The FDA Alerts below may be specifically about Amaryl or relate to a group or class of drugs which include Amaryl.

MedWatch Safety Alerts are distributed by the FDA and published by Following is a list of possible medication recalls, market withdrawals, alerts and warnings.

Recent FDA Alerts for Amaryl

Amaryl (glimepiride)

[October 26, 2004] FDA, Janssen Pharmaceutica Products, and Johnson & Johnson Pharmaceutical Research & Development notified healthcare professionals of reports of medication errors involving confusion between Reminyl, a drug approved for the treatment of mild to moderate dementia of the Alzheimer's type, and Amaryl (glimepiride), a product of Aventis Pharmaceuticals, indicated for the treatment of non-insulin dependent (Type 2) diabetes mellitus. These reports include instances in which Reminyl was prescribed but Amaryl was incorrectly dispensed and administered instead, leading to various adverse events including severe hypoglycemia and one death.

[UPDATE 12/23/2004] Letter to Pharmacists from Aventis Pharmaceuticals posted.

[October 15, 2004 - Letter to Healthcare Professionals - Janssen]
[October 19, 2004 - Letter to Pharmacists - Janssen] PDF Format
[November 5, 2004 - Letter to Pharmacists - Aventis] PDF Format

More Amaryl Resources